Abstract #1841

The Diagnostic Value of PI-RADS V2 Scoring System Combining with MRI-TRUS Fusion Targeted Biopsy for Detecting the Clinical Significant Prostate Cancer

Jie Bao¹, Xi-ming Wang¹, Chun-hong Hu¹, and Zhong-shuai Zhang²

¹The First Affiliated Hospital of Soochow University, SUZHOU, China, ²MR Scientific Marketing, Siemens Healthcare, Shanghai, SHANG HAI, China

Transrectal ultrasound-guided systematic (TRUS) biopsy is commonly used in clinical practice to detect clinically significant prostate cancer (PCa)^[1-3]. In this study, a more advanced biopsy, MRI-TRUS fusion targeted biopsy, is used together with MRI-derived PI-RADS V2 scoring system for the diagnosis of clinical significant PCa. The values of the two biopsy methods are compared.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.